Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company based in San Diego, CA, specializing in the development of targeted immunotherapies for the treatment of solid tumors. Their innovative approach involves using off-the-shelf stem cells to deliver a viral payload that not only kills cancer cells locally but also activates the immune system to fight metastatic disease. By transforming immunologically cold tumors into hot ones, Calidi's treatments engage the immune system to attack both primary tumors and distant metastases.
With a team of dedicated experts and visionaries, Calidi Biotherapeutics is pioneering the future of biotherapeutics. They are currently conducting a Phase 1 clinical trial, funded by the California Institute of Regenerative Medicine, to evaluate the efficacy of neural stem cells engineered to carry an oncolytic virus in recurrent high-grade glioma patients. Through their robust pipeline of next-generation therapies, Calidi aims to redefine cancer treatment and create a world free from the threat of cancer.
Generated from the website